SBIR/STTR Research Award

Stasis technology for storage and transport of natural and engineered tissues

Award identifier d0e3cdca84e34188e8d176aca483e7bd195d88c29801a1b64a90568bf6d87f08Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,861

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TISSUE TESTING TECHNOLOGIES LLC
Proposal award date
2016-09-01
Contract end date
2019-02-28
UEI
ZSY2J1RRALT5
Solicitation number
HL15-008
Topic code
NHLBI

Research abstract

This proposal is focused on developing innovative new cryopreservation techniques employing ice free preservation methods that will lead to the ability to bank complex vascularized tissue and organ grafts Banking of large or complex tissues such as limbs and organs using current tissue banking practices employing conventional cryopreservation by freezing is not possible due to the well known damage caused by intra and extra cellular ice formation The company team has developed vitrification cryopreserved storage in a glassy rather than crystalline ice phase for banking of small tissue samples including blood vessels heart valve tissues and cartilage However scale up to larger tissues more complex tissues and organs needs better ice control during rewarming with less risk of cytotoxicity Our collaborators Professor Duman University of Notre Dame and Professor Ben University of Ottawa have developed natural and synthetic antifreeze compounds respectively that demonstrate benefits in frozen cell systems Duman has developed recombinant insect derived antifreeze proteins and isolation methods for antifreeze glycolipids from several insects and a plant that are very effective at ice control Ben has developed a chemical library that was originally based upon an antifreeze glycoprotein derived from a deep sea teleost We will evaluate the best of these compounds during ice free cryopreservation using a vascular tissue model to determine if they improve ice control during rewarming and reduce the risk of cryoprotectant toxicity by allowing lower cryoprotectant concentrations to be used There are three specific aims in this Phase I feasibility study to identify potentially marketable methods to increase efficacy and minimize tissue damage during cryopreservation of complex natural and engineered tissues In Specific Aim we will prepare of test compounds antifreeze glycolipids from natural sources and synthesize large quantities of synthetic antifreeze compounds A stock of recombinant insect derived antifreeze proteins is already available In Specific Aim we will evaluate the impact of antifreeze compounds individually upon ice free cryopreserved blood vessels and in Specific Aim the best antifreeze supplements will be combined Evaluations will include ice control during ice free vitrification and tissue viability and function assays The technology developed in this proposal will be equally effective for stasis storage of engineered tissue constructs as natural tissues This work will lead to the development of banking by us and other cryobiology groups for internal organs such as livers and hearts vascularized composite allografts such as larynx trachea abdominal wall knee skeletal muscles facial tissues and legs as well as improved methods for critical natural and engineered tissues such as skin heart valves and blood vessels Effective new preservation solutions and protocols are needed as novel complex tissue and organ therapies are developed According to some estimates over of all U S deaths could be prevented or delayed by an organ transplant and broader tissue engineering In the U S organ impairment leads to more deaths than cancer and chronic organ impairment makes up a substantial fraction of these deaths The development of effective cryopreservation methods for large complex tissues and organs would enable upon demand availability of matched banked donor derived tissues and organs Commercialization of antifreeze compound formulations and protocols developed in this proposal will be accomplished by a combination of products cryoprotectant formulations cryopreserved tissue based test systems licensing and clinical processing services to provide important enabling storage technologies for development of multi billion dollar cell and tissue product opportunities

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

22 SBIR/STTR records share this UEI (2014–2023). Reported award amounts total $9,665,888. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.